Cybin and Kernel Announce Results from Kernel Flow® Piloting of Feasibility Study Measuring Ketamine’s Effects on the Brain
– Preliminary data confirm Flow’s ability to successfully measure neuro-effect of ketamine over 10 days – – Results to be presented at PSYCH Symposium taking place in London on May 11, 2022 – LOS ANGELES & TORONTO–(BUSINESS WIRE)–#biotech—Kernel, a leader in non-invasive neuroimaging, and Cybin Inc. (NEO:CYBN) (NYSE American:CYBN), a biopharmaceutical company focused on progressing […]